RNA, U6 small nuclear 819, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-819P profile across patient tissues and cancer cell-line models. RNU6-819P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-819P is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, RNU6-819P RNA expression shows 8,853 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, LUSC, and COAD as cancer lineages where RNU6-819P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-819P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-819P survival associations across molecular data types. RNU6-819P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-819P RNA expression–survival associations across cancer types. High RNU6-819P expression shows unfavorable associations in BLCA, HNSC, LIHC, BRCA and KIRP, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU6-819P RNA expression.
This table summarizes RNU6-819P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-819P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-819P shows higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher RNU6-819P RNA expression in tumor versus normal tissue (log2 FC = +0.123, t-test p = .014).
This table shows molecular features associated with RNU6-819P in patient tissues and cancer cell lines. In patient samples, RNU6-819P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
